P75.03 KEYNOTE-U01: A Phase 2 Umbrella Study of Investigational Agents Plus Pembrolizumab-Based Therapy for Advanced NSCLC

Pembrolizumab, an anti‒PD-1 antibody, has shown improvements in clinical outcomes versus platinum-based chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) as monotherapy in both the first- and second-line settings among patients with PD-L1‒positive NSCLC, and in combination with chemotherapy in the first-line setting, irrespective of tumor PD-L1 expression. KEYNOTE-U01 (NCT04165798) is an ongoing phase 2 umbrella study to evaluate the efficacy and safety of investigational agents in combination with pembrolizumab monotherapy or pembrolizumab plus chemotherapy in patients with advanced NSCLC using an adaptive design.